zika
viru
zikv
emerg
arboviru
belong
genu
flaviviru
compris
import
public
health
virus
dengu
denv
yellow
fever
yfv
gener
zikv
infect
selflimit
diseas
howev
case
syndrom
congenit
brain
abnorm
newborn
infant
report
diagnos
zikv
infect
remain
challeng
viral
rna
detect
applic
day
onset
symptom
serolog
test
must
appli
expect
high
crossreact
zikv
flaviviru
serolog
observ
plaqu
reduct
neutral
test
prnt
indic
confirm
posit
sampl
specif
howev
labori
intens
time
consum
repres
major
bottleneck
patient
diagnosi
overcom
limit
develop
highthroughput
imagebas
fluoresc
neutral
test
zikv
infect
serolog
detect
use
human
specimen
show
new
test
present
higher
throughput
tradit
prnt
maintain
correl
result
furthermor
test
dengu
viru
sampl
show
less
cross
reactiv
macelisa
fluoresc
neutral
test
could
use
clinic
diagnosi
confirm
zikv
infect
well
vaccin
clinic
trial
seropreval
studi
sinc
denv
cousin
known
zikv
spotlight
caught
research
attent
rapidli
spread
worldwid
zikv
infect
associ
syndrom
case
congenit
brain
abnorm
newborn
infant
close
relat
differenti
denv
zikv
infect
challeng
among
assay
use
viral
serolog
diagnosi
plaquereduct
neutral
test
prnt
describ
seem
specif
although
plo
neglect
tropic
diseas
http
doifund
cnd
receiv
financi
support
bnde
fellowship
cnpq
cape
brazilian
government
agenc
fund
research
nevertheless
fund
public
fee
limit
funder
role
studi
design
data
collect
longstand
labori
capabl
test
larg
number
sampl
therefor
develop
imag
base
neutral
test
zikv
overcom
restrict
present
prnt
new
test
faster
robust
abl
test
mani
sampl
simultan
success
distinguish
zikv
infect
infect
dengu
yellow
fever
may
especi
relev
solv
case
congenit
disord
newborn
also
elucid
agent
involv
neuropatholog
outcom
syndrom
also
use
serolog
survey
vaccin
studi
highthroughput
imagebas
neutral
test
zika
viru
serolog
diagnosi
plo
neglect
tropic
diseas
http
zika
viru
zikv
mosquitoborn
flaviviru
belong
flavivirida
famili
close
relat
dengu
viru
denv
flaviviru
virion
present
posit
singlestrand
rna
genom
approxim
kb
singl
open
read
frame
encod
one
polyprotein
cleav
structur
c
prm
e
nonstructur
protein
zikv
first
isol
sentinel
monkey
uganda
consid
endem
africa
asia
small
epidem
report
yap
state
feder
state
micronesia
anoth
zikv
outbreak
report
french
polynesia
zikv
emerg
brazil
rapidli
spread
countri
territori
america
confirm
autochthon
zikv
transmiss
previou
outbreak
ill
character
rash
conjunct
subject
fever
arthralgia
arthriti
infect
appear
rel
mild
selflimit
nonleth
howev
recent
outbreak
associ
syndrom
congenit
brain
abnorm
newborn
infant
mother
infect
zikv
pregnanc
observ
evid
indic
unequivoc
diagnosi
ill
utmost
import
correct
clinic
manag
especi
case
pregnant
women
zikv
diagnosi
base
clinic
epidemiolog
laboratori
criteria
sampl
collect
day
onset
symptom
viral
rna
often
identifi
serum
urin
rtpcr
prefer
test
zikv
also
denv
chikungunya
viru
chikv
detect
period
igm
antibodi
may
detect
elisa
howev
flavivirus
strong
crossreact
may
gener
fals
posit
result
serolog
test
make
diagnosi
zikv
infect
quit
challeng
especi
diseas
emerg
region
flavivirus
endem
therefor
plaquereduct
neutral
test
prnt
indic
measur
virusspecif
neutral
antibodi
may
abl
determin
etiolog
infect
classic
viru
prnt
first
describ
consid
gold
standard
measur
neutral
antibodi
virus
although
specif
labori
therefor
readili
amen
highthroughput
make
difficult
use
largescal
surveil
vaccin
trial
studi
describ
fast
robust
test
measur
neutral
antibodi
zikv
suitabl
highthroughput
screen
larg
collect
serum
specimen
new
assay
base
quantit
immunofluoresc
alli
classic
prnt
format
modern
readout
method
aed
albopictu
cell
atcc
grown
leibovitz
medium
gibcoinvitrogen
grand
island
ny
usa
supplement
fetal
bovin
serum
fb
gibcoinvitrogen
grand
island
ny
usa
tryptos
sigmaaldrich
st
loui
mo
usa
gentamicin
gibcoinvitrogen
grand
island
ny
usa
humanderiv
hepatoma
cell
huh
atcc
grown
dulbecco
modifi
eagl
medium
nutrient
mixtur
medium
gibcoinvitrogen
grand
island
ny
usa
supplement
fb
penicillinstreptomycin
gibco
invitrogen
grand
island
ny
usa
humidifi
co
control
atmospher
hybridoma
cultiv
medium
gibcoinvitrogen
grand
island
ny
usa
mm
hepe
supplement
fb
mm
sodium
piruv
ngml
amphotericin
b
penicillinstreptomycin
zikv
strain
zv
br
isol
patient
zika
fever
northeast
brazil
dengu
virus
four
serotyp
use
isol
south
american
patient
dengu
fever
genbank
den
genbank
isol
brazil
genbank
isol
nonfat
case
dengu
hemorrhag
manifest
obtain
viral
stock
viru
propag
multipl
infect
moi
titrat
focu
form
assay
total
sera
use
studi
approv
fiocruz
brazilian
nation
ethic
committe
human
experiment
caae
well
waiver
inform
consent
specimen
divid
follow
posit
sera
zikv
confirm
igm
elisa
andor
real
time
rtpcr
igg
sera
posit
denv
confirm
panbio
igg
indirect
elisa
aler
brisban
australia
igm
sera
posit
denv
serotyp
confirm
igm
captur
elisa
rtpcr
sera
yellow
fever
viru
vaccin
volunt
neg
sera
addit
panel
sampl
posit
acut
infect
test
panel
includ
sera
posit
toxoplasmosi
sampl
epsteinbarr
viru
ebv
vener
diseas
research
laboratori
test
vdrl
cytomegaloviru
cmv
cmvebv
leptospirosi
hantaviru
except
zika
posit
sera
sampl
collect
prior
zikv
emerg
latin
america
zika
posit
sera
receiv
laboratori
sinc
zikv
outbreak
brazil
design
sentinel
laboratori
brazilian
ministri
health
thu
work
zikv
diagnosi
south
region
huh
cell
plate
well
plate
densiti
cell
previou
infect
serum
sampl
inactiv
min
dilut
follow
serial
dilut
equal
volum
viru
suspens
contain
plaqueform
unit
pfu
mix
dilut
sampl
incub
room
temperatur
step
mixtur
inocul
onto
plate
cell
incub
inoculum
discard
overlay
cmc
fb
medium
ad
plate
left
day
cell
fix
paraformaldehyd
stain
crystal
violet
plaqu
count
antibodi
titer
determin
serum
dilut
inhibit
test
viru
inoculum
prnt
huh
cell
plate
well
plate
densiti
cell
previou
infect
serum
sampl
inactiv
min
dilut
describ
equal
volum
viru
suspens
moi
pfu
mix
dilut
sampl
incub
room
temperatur
mixtur
inocul
onto
plate
cell
incub
inoculum
replac
fresh
medium
plate
incub
cell
fix
cold
methanolaceton
vv
immunostain
monoclon
antibodi
use
stain
viru
envelop
protein
dilut
block
buffer
pb
bsa
incub
well
wash
three
time
wash
buffer
pb
tween
incub
secondari
antibodi
antimous
igg
alexa
fluor
molecular
probe
block
buffer
cell
nuclei
counterstain
thermo
fisher
scientif
wash
three
time
wash
buffer
imag
obtain
operetta
highcont
imag
system
perkinelm
object
long
wd
number
imag
necessari
repres
entir
well
defin
analyz
harmoni
highcont
imag
analysi
softwar
perkinelm
fig
percentag
infect
cell
obtain
normal
relat
posit
neg
control
antibodi
titer
determin
serum
dilut
inhibit
viral
infect
nt
zika
igm
antibodi
captur
enzymelink
immunosorb
assay
macelisa
perform
accordingli
guidelin
cdc
minor
modif
human
monoclon
antibodi
mab
antiflaviviru
kindli
provid
cdc
use
posit
control
antigen
zikv
mock
deriv
inactiv
cellcultur
supernat
noninfect
zikv
infect
cell
zikv
genom
detect
viral
rna
extract
sampl
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
realtim
rtpcr
perform
describ
lanciotti
et
al
use
rna
gotaq
probe
rtqpcr
system
promega
assay
perform
lightcycl
instrument
roch
mannheim
germani
human
rnase
p
use
endogen
control
assay
qualiti
assess
z
standard
deviat
mean
posit
p
neg
n
control
result
consid
z
higher
neutral
curv
obtain
use
softwar
prism
graphpad
version
usa
prnt
nt
calcul
log
agonist
vs
responsefind
ecanyth
curv
hillslop
develop
valid
newli
propos
fluoresc
neutral
test
potenti
substitut
low
throughput
labor
intens
classic
prnt
test
sever
paramet
seek
reproduc
faster
result
zikv
strain
zv
br
chosen
recent
brazilian
clinic
isol
therefor
good
repres
test
serum
sampl
region
viral
stock
obtain
second
viral
passag
use
low
multipl
infect
moi
cell
line
due
good
infect
rate
low
cytotox
kinet
viru
growth
perform
third
tenth
day
infect
fig
determin
time
point
recov
cultur
supernat
viral
stock
harvest
fifth
day
infect
middl
end
exponenti
phase
growth
avoid
high
concentr
defect
interf
particl
could
lead
fals
low
neutral
titer
huh
humanderiv
hepatoma
cell
line
chosen
neutral
assay
permiss
zikv
flaviviru
infect
also
automat
well
segment
softwar
tool
appropri
cell
seed
densiti
defin
cell
per
well
mm
sinc
suffici
high
number
cell
enough
spatial
distribut
proper
identif
accur
analysi
moi
use
experi
condit
yield
around
infect
cell
fig
cell
infect
visual
indirect
immunofluoresc
assay
detect
zikv
e
protein
mab
secondari
antimous
igg
alexa
fluor
nuclei
counterstain
four
imag
per
well
repres
whole
well
acquir
operetta
highcont
imag
system
analyz
harmoni
analysi
softwar
perkinelm
standard
step
proceed
neutral
assay
serum
specimen
heat
inactiv
reduc
effect
complement
factor
may
final
result
serum
viru
sampl
mix
allow
neutral
incub
period
mixtur
ad
cell
infect
could
occur
nonneutr
viru
neutral
titer
inhibit
viral
infect
nt
use
analyz
result
fig
criteria
follow
order
accept
valid
assay
among
uniform
number
cell
per
well
appropri
percent
infect
control
serum
toxic
observ
low
serum
dilut
z
higher
order
observ
interassay
variabl
one
neg
one
posit
sampl
test
three
independ
assay
observ
low
variat
neg
prnt
gold
standard
measur
flaviviru
neutral
therefor
neutral
titer
obtain
serum
sampl
use
either
new
fluoresc
neutral
test
classic
prnt
compar
similar
neutral
result
obtain
two
approach
correl
fig
demonstr
robust
newli
develop
test
could
use
replac
tradit
test
use
interpret
guidanc
suggest
cdc
new
propos
test
valid
set
serum
sampl
previous
test
panel
includ
sera
posit
flaviviru
nonflaviviru
acut
infect
neg
serum
tabl
zika
posit
sampl
collect
diseas
outbreak
brazil
sampl
collect
previou
zikv
emerg
countri
sampl
submit
fluoresc
neutral
test
nt
calcul
fig
follow
recommend
interpret
neutral
result
titer
higher
suppos
consid
posit
howev
observ
sever
igm
posit
sampl
dengu
would
erron
consid
posit
zikv
therefor
restrict
result
interpret
employ
follow
sampl
consid
neg
nt
inconclus
nt
posit
nt
even
higher
cutoff
valu
possibl
observ
six
denv
igm
sampl
crossreact
zikv
neutral
assay
anoth
sampl
inconclus
cross
reactiv
observ
sampl
denv
igg
acut
infect
yfv
vaccin
analyz
regard
zika
posit
panel
tabl
pair
sampl
present
blue
fig
obtain
four
patient
first
collect
rtpcr
posit
present
low
nt
titer
second
collect
obtain
month
first
one
neutral
titer
increas
level
lot
higher
cut
valu
fig
assess
cross
reactiv
zikv
denv
infect
macelisa
format
assay
fluoresc
neutral
test
denv
wellcharacter
posit
sampl
test
tabl
neutral
titer
sampl
present
tabl
thu
novel
neutral
test
present
less
cross
reactiv
macelisa
rate
correct
identif
zikv
neg
serum
increas
fluoresc
neutral
test
format
expand
diseas
proof
concept
test
adapt
identifi
neutral
antibodi
dengu
viru
standard
step
use
previous
employ
develop
test
four
serotyp
denv
optim
harvest
time
viral
stock
th
day
infect
order
obtain
around
infect
moi
use
denv
fluoresc
neutral
test
abl
identifi
neutral
antibodi
four
serotyp
viru
denv
igm
posit
sampl
test
tabl
howev
possibl
identifi
denv
serotyp
respons
current
infect
accord
fluoresc
neutral
assay
result
indic
probabl
secondari
denv
infect
sinc
zikv
emerg
south
america
caus
number
outbreak
report
case
associ
syndrom
congenit
brain
abnorm
newborn
infant
great
effort
develop
specif
reliabl
diagnosi
test
made
definit
zikv
diagnosi
achiev
detect
viral
rna
patient
serum
sampl
like
urin
semen
placenta
although
rtpcr
assay
trustworthi
good
sensit
specif
viremia
among
zikvinfect
patient
rel
low
detect
day
onset
symptom
individu
beyond
viremia
window
serolog
test
must
employ
common
use
method
detect
reactiv
igm
antibodi
elisa
disadvantag
highthroughput
imagebas
neutral
test
zika
viru
serolog
diagnosi
use
option
zikv
high
number
fals
posit
result
due
crossreact
antibodi
denv
low
sensit
exist
immunoassay
novel
elisa
base
recombin
zikv
nonstructur
protein
abl
elimin
crossreact
antibodi
denv
flavivirus
although
present
low
sensit
igm
format
order
overcom
issu
cdc
diagnost
guidelin
recommend
presumpt
posit
equivoc
macelisa
result
zikv
need
verifi
confirmatori
prnt
previou
state
although
prnt
gold
standard
flaviviru
serolog
test
number
limit
prevent
use
larg
scale
test
great
number
sampl
requir
outbreak
perform
serolog
survey
addit
recommend
serolog
test
asymptomat
pregnant
women
histori
travel
zikv
endem
region
live
area
activ
viral
transmiss
studi
describ
develop
valid
novel
imag
base
neutral
test
zikv
overcom
restrict
present
prnt
previou
studi
develop
assay
replac
denv
prnt
vorndam
beltran
develop
evalu
microneutr
test
measur
antidengu
antibodi
use
situ
elisa
addit
format
flow
cytometrybas
neutral
assay
propos
similar
neutral
pattern
observ
compar
classic
prnt
disadvantag
observ
includ
high
intraassay
variabl
need
remov
adher
cell
well
recent
altern
assay
zikv
prnt
also
report
mttbase
cell
viabil
assay
zikv
neutral
antibodi
quantif
develop
although
requir
expens
equip
costli
reagent
depend
furthermor
neutral
assay
endpoint
measur
realtim
pcr
propos
novel
fluoresc
neutral
assay
develop
combin
classic
neutral
protocol
new
automat
readout
method
employ
highcont
imag
system
seed
cell
obtain
result
new
test
take
around
contrast
prnt
take
day
also
depend
manual
count
plaqu
vari
person
person
besid
new
assay
abl
test
least
ten
serum
sampl
viru
singl
plate
dilut
perform
via
multichannel
pipet
devic
increas
assay
capac
maistriau
et
al
also
propos
fluoresc
neutral
test
use
highthroughput
imag
acquisit
system
howev
base
transloc
transcript
factor
respons
infect
thu
requir
care
select
cell
line
accord
viru
interest
contrast
propos
robust
simpl
method
easili
set
investig
flaviviru
infect
studi
curv
fit
method
sever
serum
dilut
use
calcul
neutral
titer
allow
precis
result
contrast
simpli
report
reciproc
last
serum
dilut
show
reduct
infect
neutral
titer
inhibit
viral
infect
nt
use
indic
epidemiolog
studi
diagnost
purpos
endem
area
decreas
background
serum
crossreact
among
flavivirus
report
peopl
expos
secondari
denv
infect
develop
broadli
neutral
antibodi
neutral
differ
serotyp
one
respons
current
infect
also
demonstr
denv
fluoresc
neutral
test
tabl
addit
sera
patient
secondari
denv
infect
exhibit
potent
crossreact
zikv
context
cross
reactiv
zikv
denv
quit
expect
virus
envelop
protein
share
high
degre
homolog
sequenc
ident
nearli
ident
structur
fusion
loop
import
antibodi
target
conserv
two
virus
therefor
increas
specif
serolog
test
particularli
relev
sinc
zikv
emerg
flaviviru
endem
region
aim
reduc
fals
posit
result
sampl
consid
zikv
posit
nt
nt
sampl
score
neg
nt
rang
result
record
inconclus
studi
also
use
higher
cut
prnt
valu
base
paramet
higher
specif
achiev
compar
macelisa
yield
less
zikv
fals
posit
result
denv
igm
posit
serum
sampl
inconclus
fals
posit
result
observ
set
result
particularli
remark
sinc
anoth
assay
cross
reaction
zikv
observ
acut
convalesc
sera
nine
thai
patient
confirm
denv
infect
rtpcr
test
bind
neutral
assay
anoth
studi
use
rvnt
antizikv
antibodi
detect
show
erron
result
presenc
antidenv
antibodi
although
fals
posit
result
yellow
fever
west
nile
posit
sampl
observ
realtim
pcr
neutral
assay
also
report
signific
crossreact
test
serum
specimen
patient
proven
current
zikv
infect
background
denv
infect
noteworthi
higher
cut
valu
may
reduc
assay
sensibl
ie
sampl
zikv
earli
infect
becom
inconclus
case
molecular
diagnosi
employ
second
serum
collect
test
sinc
antibodi
might
yet
reach
detect
level
observ
pair
sampl
test
increas
neutral
titer
observ
conclus
develop
fluoresc
neutral
test
offer
signific
advantag
classic
prnt
faster
prompt
high
throughput
adapt
autom
read
result
specif
macelisa
assay
expect
also
present
limit
discrimin
antibodi
class
requir
expens
equip
perform
select
laboratori
nevertheless
make
possibl
test
simultan
larg
number
sampl
differ
virus
assist
correct
manag
suspect
patient
asymptomat
pregnant
woman
employ
seropreval
survey
